Gilead Sciences Buys CymaBay Therapeutics for $4.3B, Boosting Liver Disease Treatment Options
Gilead Sciences is acquiring CymaBay Therapeutics for $4.3 billion, enhancing its liver disease portfolio with seladelpar, a drug for primary biliary cholangitis.
UMass Amherst Study Reveals Higher Gas Costs for Drivers in Massachusetts' Lower-Income Areas Due to Poor Roads
A UMass Amherst study found that poor road conditions in Massachusetts' disadvantaged areas cause higher fuel consumption, disproportionately affecting these communities financially.
Harvard's Health Alert: Cut Cancer Risk with Diet Overhaul, Experts Dish Out the Dirt on Deadly Foods
Harvard experts discuss how diets rich in ultra-processed foods, alcohol, and processed meats increase cancer risk, emphasizing the benefits of fruits, vegetables, whole grains, healthy proteins, and cooking at home.
Artificial Intelligence is Revolutionizing Golf with AI Caddies and High-Tech Greens
Artificial intelligence is significantly enhancing golf, with technologies like ShotLink providing real-time shot tracking and AI-driven gear customization, improving experiences for players and spectators.












